Novartis' oral medication, Fabhalta, has received full FDA approval to slow the decline of kidney function in adult patients with primary IgA nephropathy (IgAN). This approval, following a priority review, positions Fabhalta as a significant treatment option that could delay the need for dialysis or transplant in at-risk patients, based on strong Phase 3 clinical trial data.
Novartis (NVS) has secured full FDA approval for its drug Fabhalta (iptacopan) for primary IgA nephropathy (IgAN), a significant milestone. This approval is based on Phase 3 trial data showing Fabhalta significantly slows kidney function decline, potentially delaying dialysis or transplant for patients. This is a positive development for Novartis, expanding its kidney disease portfolio and offering a new, first-in-class treatment for a prevalent autoimmune kidney disorder. The short-term implication is a boost to NVS's market position and revenue potential for this drug, while long-term, it solidifies its presence in the nephrology market. The key opportunity for traders is the potential for increased sales and market share for NVS in the IgAN treatment space.